Genetic testing company 23andMe has had a rough few years. A data breach in October 2023 resulted in the exfiltration of over 14,000 customers’ genetic data to foreign threat actors, which spurred a series of lawsuits in the Northern District of California and likely contributed to the company’s already declining stock price.
As of November, shares of 23andMe were down 99% from its peak in 2021. If forced to declare bankruptcy, the company could put its trove of genetic data up for sale to pay off some debts. Concerned customers may be wondering whether this is even legal.
For the ...